Bromo-DragonFLY

Bromo-DragonFLY, also known as ABDF, is a psychedelic hallucinogenic drug related to the phenethylamine family. Bromo-DragonFLY is considered an extremely potent hallucinogen, only slightly less potent than LSD with a normal dose in the region of 200μg to 800μg, and it has an extremely long duration of action. It is explicitly illegal only in Sweden^{[citation needed]} and Denmark, although it may be considered a controlled substance analogue under US and Australian drug laws. Bromo-DragonFLY has a stereocenter and R-(-)-bromo-DragonFLY is the more active stereoisomer.

Additional recommended knowledge

How to ensure accurate weighing results every day?

Daily Visual Balance Check

Better weighing performance in 6 easy steps

Pharmacology

The hallucinogenic effect of bromo-DragonFLY is mediated by its agonist activity at the 5-HT_2A serotonin receptor. Bromo-DragonFLY also has a high binding affinity for the 5-HT_2B and 5-HT_2C serotonin receptors.

Dosage

Bromo-DragonFLY can sometimes be found on "blotters" (small bits of paper containing the substance) similar to the most commonly found distribution method of LSD, thus making it difficult to identify which substance it is carrying. Two deaths have been associated with the ingestion of bromo-dragonFLY in Sweden and Norway ^[1].

History

Bromo-DragonFLY was first synthesized by Matthew A. Parker in the laboratory of David E. Nichols in 1998.

Legal Status

Denmark

As of December 5, 2007 the drug will be banned by law in Denmark. The substance has been deemed illegal in the category of controlled substances by the Danish health minister Jakob Axel Nielsen, after recommandation by the Danish Health Ministry. As of December 5, 2007 the drug is considered a narcotic in Denmark and hence illegal to posses, import and use. Erowid Bromo-Dragonfly vault

See also

• 2C-B
• DOB
• 2C-B-FLY
• PiHKAL
• 5-HT_2A receptor

References

1. ^ http://www.erowid.org/chemicals/bromo_dragonfly/bromo_dragonfly_death1.shtml

• 'A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT_2A receptor' by M. A. Parker, D. Marona-Lewicka, V. L. Lucaites, D. L. Nelson, and D. E. Nichols in J. Med. Chem. 41(26): 5148-5149 (1998) DOI: 10.1021/jm9803525
• 'Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT_2A/2C receptor agonists' by J. J. Chambers, D. M. Kurrasch-Orbaugh, M. A. Parker, and D. E. Nichols in J. Med. Chem. 44(6): 1003-1010 (2001) DOI: 10.1021/jm000491y
• 'Man i 20-årsåldern dog av drogen Dragonfly', Kajsa Hallberg, Tipsa Expressen, 3 April 2007. http://jonkoping.expressen.se/Nyheter/1.622826